Pfizer
- Market Cap
- ₹17,640 Cr
- P/E
- 20.53
Key Fundamentals
SmallcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 24.10%
- Debt to Equity
- 0.04
- EPS (TTM)
- ₹187.85
- Book Value
- ₹958.74
- Market Cap
- ₹17,640 Cr
- P/E (TTM)
- 20.53
- P/B
- 4.02
- ROE
- 18.00%
- Dividend Yield
- 1.95%
- EBITDA
- ₹1,092 Cr
- 52W High
- ₹5,257.00
- 52W Low
- ₹3,589.00
- Day Range
- ₹3,816.00 – ₹3,872.00
- Volume
- 13,808
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| 3,856.00 | 20.53 | 17,640 | 4.02 | 1.95% | 18.00% | 24.10% | 2,654 | 859 | |
| Median 8 companies | 2,089.75 | 41.35 | 1,21,840 | 4.69 | 0.70% | 17.25% | 19.15% | 22,770 | 2,808 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 73
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 82
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 39
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 84
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 18
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 44
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 58.3%
Weaknesses
1- The company has delivered a poor sales growth of 2.39% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 7 | 7 | 5 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bearish | 7 | 0 | 3 |
Oscillators
Bullish
Overall
Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 50.14
- Neutral
- MACD (12,26,9)
- −11.78
- Bullish
- SMA (50)
- 3,874.48
- Bearish
- SMA (200)
- 4,521.76
- Bearish
As of
Analyst Rating
4 of 5 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +2.28% |
|---|---|
| 5Y | +2.39% |
| 3Y | +1.29% |
| 1Y | +10.48% |
| TTM | +11.75% |
Net profit
| 10Y | +9.00% |
|---|---|
| 5Y | +7.71% |
| 3Y | +4.98% |
| 1Y | −5.99% |
| TTM | +2.26% |
Operating cash flow
| 10Y | +10.87% |
|---|---|
| 5Y | +17.78% |
| 3Y | +39.58% |
| 1Y | +46.67% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +14.35 pp |
|---|---|
| 5Y | +4.07 pp |
| 3Y | +2.51 pp |
| 1Y | +3.34 pp |
| TTM | +2.39 pp |
Revenue by year
| Mar 2017 | ₹1,966 Cr |
|---|---|
| Mar 2018 | ₹1,969 Cr |
| Mar 2019 | ₹2,082 Cr |
| Mar 2020 | ₹2,152 Cr |
| Mar 2021 | ₹2,239 Cr |
| Mar 2022 | ₹2,611 Cr |
| Mar 2023 | ₹2,425 Cr |
| Mar 2024 | ₹2,193 Cr |
| Mar 2025 | ₹2,281 Cr |
| Mar 2026 | ₹2,520 Cr |
Net profit by year
| Mar 2017 | ₹337 Cr |
|---|---|
| Mar 2018 | ₹360 Cr |
| Mar 2019 | ₹429 Cr |
| Mar 2020 | ₹509 Cr |
| Mar 2021 | ₹498 Cr |
| Mar 2022 | ₹613 Cr |
| Mar 2023 | ₹624 Cr |
| Mar 2024 | ₹551 Cr |
| Mar 2025 | ₹768 Cr |
| Mar 2026 | ₹722 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Pfizer Ltd trades at ₹3,850.3 as of 2026-11-19 with a market cap of ₹17,614.25 crore, a PE of 20.5x, and a near-zero debt-to-equity ratio of 0.02. The company shows improving TTM profit growth of 13% but carries a legacy of sluggish revenue expansion at just 2% CAGR over five years, while the stock has declined 23% over the past one year.
- Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.02, providing significant financial flexibility and resilience against economic downturns.
- ROCE stands at 22.94%, indicating efficient deployment of capital and strong underlying business economics.
- ROE of 17.19% (current) with a consistent 10-year average of 17%, reflecting durable profitability and steady return generation for shareholders.
- Healthy dividend payout ratio of 58.3% combined with a dividend yield of 1.95%, offering meaningful income to investors at the current price of ₹3,850.3.
- TTM profit growth has accelerated to 13%, meaningfully above the 3-year compounded profit growth of 8% and the 5-year rate of 9%, suggesting an improving earnings trajectory.
- TTM sales growth of 12% marks a sharp uptick compared to the 3-year compounded sales growth of just 1% and the 5-year rate of 2%, pointing to a potential inflection in revenue momentum.
- 10-year compounded profit growth of 10% has consistently outpaced the 10-year compounded sales growth of 2%, demonstrating sustained margin expansion and operating leverage over a long period.
- Five-year compounded sales growth of only 2% highlights chronic top-line stagnation and limited ability to scale revenue over extended periods.
- The stock has delivered a 1-year return of -23% and a negative 5-year CAGR of -5%, significantly destroying shareholder value over both short and medium horizons.
- Even over a 3-year period, the stock CAGR is -2%, indicating the underperformance is not merely a short-term blip but a sustained trend.
- A price-to-book ratio of 4.02x is relatively elevated for a company growing sales at only 2% compounded over five years, raising questions about valuation support.
- The 10-year stock CAGR of 8% trails the 10-year compounded profit growth of 10%, suggesting the market has progressively de-rated the stock's earnings multiple over the long term.
- Three-year compounded sales growth of just 1% is even weaker than the 5-year figure of 2%, indicating revenue growth decelerated further in recent years before the latest TTM uptick.
- PE of 20.5x on an EPS of ₹187.85, while not extreme, demands sustained earnings growth to justify — any reversion in the TTM profit growth trend from 13% back toward the 3-year average of 8% could pressure the multiple.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Pfizer Ltd delivered a strong Q2FY27 headline with net profit up 65.7%, though stripping out the ₹132.06 crore one-time gain from the Minipress XL sale, core pre-tax profit growth was a more modest 13.86% YoY. Rising expenses and the discontinuation of Minipress XL bear watching as potential drags on future earnings. The underlying business remains healthy with steady revenue growth, but investors should monitor whether core profitability momentum sustains without non-recurring items.
- Profit boost is non-recurring Nov 3
The 65.7% net profit surge to ₹313.25 crore was primarily driven by a one-time exceptional gain of ₹132.06 crore from the Minipress XL divestiture, which will not repeat in future quarters.
- Rising operational expenses Nov 3
Total expenses increased to ₹483.2 crore in Q2FY27 from ₹428.82 crore a year ago, reflecting higher operational costs associated with business restructuring.
- Minipress XL discontinued Nov 3
Pfizer Ltd is discontinuing manufacture of Minipress XL from September 7, 2026, removing a product line from its portfolio following the sale to parent entity Pfizer Inc USA.
- Q2 net profit surges 65.7% Nov 3
Pfizer reported Q2FY27 net profit of ₹313.25 crore, up 65.7% YoY from ₹189 crore, while total income rose to ₹774.19 crore from ₹684.19 crore.
- Core PBT up 13.86% YoY Nov 3
Profit before tax and exceptional items grew 13.86% to ₹290.77 crore from ₹255.37 crore, indicating solid underlying operational improvement beyond the one-time gain.
- Share price jumps 3.37% Nov 3
Pfizer shares closed 3.37% higher at ₹3,760.50 on the BSE following the Q2 results announcement, reflecting investor confidence in the quarterly performance.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 | 653 | 727 |
| Expenses | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 | 406 | 466 |
| Operating Profit | 183 | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 | 228 | 236 | 248 | 261 |
| OPM % | 32% | 28% | 35% | 32% | 32% | 27% | 38% | 35% | 36% | 35% | 38% | 38% | 36% |
| Other Income | 36 | 35.85 | 75 | 42 | 43 | 43 | 217 | 67 | 42 | −20 | 40.72 | 45 | 47.33 |
| Interest | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 1 | 3.35 |
| Depreciation | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 | 14 | 15 | 14 | 14.41 |
| Exceptional Items | — | 7.95 | — | — | — | — | — | — | — | — | 9.04 | — | 132 |
| PBT | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 | 277 | 423 |
| Tax % | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% | 26% | 26% | 26% | 26% |
| Net Profit | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 | 204 | 313 |
| EPS (₹) | 32.56 | 28.41 | 39.10 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31.00 | 43.68 | 44.70 | 68.47 |
| YoY Sales growth | −10 | −13 | −5 | 6 | 2 | 0 | 8 | 7 | 9 | 20 | 6 | 8 | 13 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 | 2,654 |
| Expenses | 1,438 | 1,579 | 1,616 | 1,468 | 1,516 | 1,578 | 1,526 | 1,775 | 1,616 | 1,555 | 1,540 | 1,615 | 1,681 |
| Operating Profit | 414 | 433 | 350 | 501 | 566 | 574 | 712 | 836 | 809 | 638 | 742 | 904 | 973 |
| OPM % | 22% | 22% | 18% | 25% | 27% | 27% | 32% | 32% | 33% | 29% | 33% | 36% | 37% |
| Other Income | 44 | 97 | 232 | 114 | 167 | 183 | 81 | 63 | 101 | 185 | 344 | 188 | 254 |
| Interest | 2 | 1 | 2 | 0.42 | 1.29 | 11 | 15 | 10.49 | 13 | 15 | 8 | 9.48 | 9 |
| Depreciation | 250 | 58 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 | 58 | 58 |
| Exceptional Items | — | — | — | — | — | — | — | — | 33 | — | — | −49.16 | — |
| PBT | 207 | 470 | 517 | 548 | 660 | 642 | 669 | 773 | 824 | 746 | 1,016 | 976 | 1,160 |
| Tax % | 66% | 35% | 35% | 34% | 35% | 21% | 26% | 21% | 24% | 26% | 24% | 26% | — |
| Net Profit | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 722 | 859 |
| EPS (₹) | 15.26 | 66.67 | 73.62 | 78.71 | 93.79 | 111.29 | 108.77 | 133.90 | 136.38 | 120.52 | 167.79 | 157.92 | 187.85 |
| Div. Payout % | 82% | 22% | 27% | 25% | 24% | 297% | 32% | 26% | 29% | 29% | 98% | 48% | — |
| Sales growth | 67 | 9 | −2 | 0 | 6 | 3 | 4 | 17 | −7 | −10 | 4 | 10 | 12 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves | 1,927 | 2,118 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 | 4,157 | 4,340 |
| Borrowings | 2 | 2 | 2 | 2 | 2 | 2 | 63 | 39 | 41 | 40 | 108 | 70 | 197 |
| Other Liabilities | 638 | 722 | 840 | 1,004 | 926 | 1,007 | 810 | 997 | 752 | 593 | 585 | 649 | 711 |
| Total Liabilities | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 | 5,293 |
| Fixed Assets | 944 | 925 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 724 | 678 | 804 |
| CWIP | 13 | 3 | 15 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 8 | 20 | 31 |
| Investments | 43 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,614 | 1,923 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 | 4,224 | 4,457 |
| Total Assets | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 | 5,293 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 113 | 345 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | 257 | 660 | 968 |
| Investing | 68 | −701 | −250 | −238 | 35 | 1,530 | −469 | −575 | −36 | 54 | −71 | −562 |
| Financing | −1 | −62 | −83 | −110 | −110 | −164 | −1,571 | −181 | −346 | −235 | −205 | −798 |
| Net Cash Flow | 181 | −417 | −3 | −17 | 23 | 1,690 | −1,613 | −88 | −26 | 75 | 383 | −392 |
| Free Cash Flow | 93 | 398 | 394 | 262 | 125 | 343 | 410 | 654 | 292 | 291 | 783 | 944 |
| CFO/EBITDA | 62 | 120 | 146 | 105 | 59 | 93 | 89 | 107 | 81 | 64 | 110 | 105 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 26 | 20 | 29 | 30 | 29 | 18 | 20 | 23 | 31 | 31 | 26 |
| Inventory Days | 191 | 167 | 148 | 147 | 189 | 198 | 199 | 173 | 175 | 200 | 214 | 195 |
| Days Payable | 165 | 157 | 178 | 245 | 213 | 197 | 130 | 102 | 91 | 77 | 68 | 89 |
| Cash Conversion Cycle | 58 | 36 | −10 | −69 | 6 | 31 | 87 | 91 | 107 | 154 | 177 | 132 |
| Working Capital Days | 7 | −9 | −47 | −57 | −16 | −8 | 3 | −14 | 1 | 24 | 23 | 9 |
| ROCE % | 24% | 22% | 17% | 21% | 23% | 20% | 23% | 29% | 26% | 22% | 21% | 24% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Pfizer insights
65 extracted metrics across FY11–FY27.
Documents
- Q1 FY21 concall · Aug 2020Transcript
- Concall · May 2017Transcript
- Q3 FY17 concall · Feb 2017Transcript
- Concall · Nov 2016Transcript
- Q1 FY17 concall · Aug 2016Transcript
- General announcements 9 Oct 2026
- General announcements 29 Sep 2026
Frequently Asked Questions about Pfizer
What does Pfizer Ltd do?
Where is Pfizer Ltd (PFIZER) listed?
Which sector does Pfizer Ltd belong to?
What is the market capitalisation of Pfizer Ltd?
What is the PE ratio of Pfizer Ltd?
What is the 52-week high and low of Pfizer Ltd?
Does Pfizer Ltd pay dividends?
What is the Return on Equity (ROE) of Pfizer Ltd?
Company Information
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. It is the 3rd largest multinational pharmaceutical company in India.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PFIZER.md for Pfizer Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.